BI 2536

DB16107InvestigationalSmall molecule

BI 2536 is under investigation in clinical trial NCT00376623 (Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer).

Mechanism: Pharmacologically active on Serine/threonine-protein kinase PLK1
Curator reviewed
Formula / weight: C₂₈H₃₉N₇O₃ · 521.666 g/mol (avg)
Code names: BI-2536

Resolves to

Compound

Structure

InChIKeyXQVVPGYIWAGRNI-JOCHJYFZSA-NSMILESCC[C@H]1N(C2CCCC2)C2=NC(NC3=CC=C(C=C3OC)C(=O)NC3CCN(C)CC3)=NC=C2N(C)C1=O

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with BI 2536, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.